June 11, 2020 / 11:38 AM / a month ago

Takeda to divest some Asia-focused drugs to Celltrion for about $266 mln

June 11 (Reuters) - Takeda Pharmaceutical Co Ltd said on Thursday it will divest some over-the-counter and prescription drugs sold exclusively in Asia Pacific to South Korea’s Celltrion Inc.

Takeda will get $266 million upfront in cash and up to an additional $12 million in potential milestone payments, the company said. (Reporting By Mrinalika Roy in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below